Securities Class Action Filed Against Aldeyra Therapeutics Over Reproxalap Trial Data
ALDX sits 50% above its 52-week low of $1.07 on light trading volume (0.3× avg).
Summary
Aldeyra Therapeutics is facing a securities class action lawsuit, with a lead plaintiff deadline of May 29, 2026. The lawsuit alleges that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials, rendering purported positive findings unreliable. This legal action follows the devastating FDA Complete Response Letter for reproxalap, which cited a lack of efficacy and led to AbbVie's non-exercise of a lucrative option agreement. The class action introduces additional legal and financial risks for Aldeyra, compounding the challenges already presented by the regulatory setback for its lead drug candidate.
At the time of this announcement, ALDX was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.5M. The 52-week trading range was $1.07 to $6.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.